Literature DB >> 16919727

S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes.

Mirko Völkers1, Christopher M Loughrey, Niall Macquaide, Andrew Remppis, Brent R DeGeorge, Frederic V Wegner, Oliver Friedrich, Rainer H A Fink, Walter J Koch, Godfrey L Smith, Patrick Most.   

Abstract

S100A1, a Ca2+-sensor protein of the EF-hand type, exerts positive inotropic effects in the heart via enhanced cardiac ryanodine receptor (RyR2) activity. Here we report that S100A1 protein (0.1microM) interacts with the RyR2 in resting permeabilized cardiomyocytes at free Ca2+-levels comparable to diastolic Ca2+-concentrations ( approximately 150nM). Alterations of RyR2 function due to S100A1 binding was assessed via analysis of Ca2+-spark characteristics. Ca2+-spark frequency, amplitude and duration were all reduced upon perfusion with 0.1microM S100A1 protein by 38%, 14% and 18%, respectively. Most likely, these effects were conveyed through the S100A1 C-terminus (S100A1-ct; amino acids 75-94) as the corresponding S100A1-ct peptide (0.1microM) inhibited S100A1 protein binding to the RyR2 and similarly attenuated frequency, amplitude and duration of Ca2+-sparks by 52%, 8% and 26%, respectively. Accordingly, the sarcoplasmic reticulum (SR) Ca2+-content was slightly increased but the stoichiometry of other accessory RyR2 modulators (sorcin/FKBP12.6) remained unaltered by S100A1. Hence, we propose S100A1 as a novel inhibitory modulator of RyR2 function at diastolic Ca2+-concentrations in rabbit ventricular cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919727     DOI: 10.1016/j.ceca.2006.06.001

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  29 in total

Review 1.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

2.  Modulation of sarcoplasmic reticulum Ca2+ release in skeletal muscle expressing ryanodine receptor impaired in regulation by calmodulin and S100A1.

Authors:  Naohiro Yamaguchi; Benjamin L Prosser; Farshid Ghassemi; Le Xu; Daniel A Pasek; Jerry P Eu; Erick O Hernández-Ochoa; Brian R Cannon; Paul T Wilder; Richard M Lovering; David Weber; Werner Melzer; Martin F Schneider; Gerhard Meissner
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-02       Impact factor: 4.249

Review 3.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

4.  S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.

Authors:  Julia Ritterhoff; Mirko Völkers; Andreas Seitz; Kristin Spaich; Erhe Gao; Karsten Peppel; Sven T Pleger; Wolfram H Zimmermann; Oliver Friedrich; Rainer H A Fink; Walter J Koch; Hugo A Katus; Patrick Most
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 5.  Gene therapy targets in heart failure: the path to translation.

Authors:  P W J Raake; H Tscheschner; J Reinkober; J Ritterhoff; H A Katus; W J Koch; P Most
Journal:  Clin Pharmacol Ther       Date:  2011-08-24       Impact factor: 6.875

Review 6.  Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy.

Authors:  Changwon Kho; Ahyoung Lee; Roger J Hajjar
Journal:  Nat Rev Cardiol       Date:  2012-10-23       Impact factor: 32.419

7.  S100A1 in human heart failure: lack of recovery following left ventricular assist device support.

Authors:  Mosi K Bennett; Wendy E Sweet; Sara Baicker-McKee; Elizabeth Looney; Kristen Karohl; Maria Mountis; W H Wilson Tang; Randall C Starling; Christine S Moravec
Journal:  Circ Heart Fail       Date:  2014-05-19       Impact factor: 8.790

Review 8.  Heart failure management: the present and the future.

Authors:  Mohammad N Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

Review 9.  S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function.

Authors:  Mirko Völkers; David Rohde; Chelain Goodman; Patrick Most
Journal:  J Biomed Biotechnol       Date:  2010-03-28

Review 10.  S100A1: a multifaceted therapeutic target in cardiovascular disease.

Authors:  David Rohde; Julia Ritterhoff; Mirko Voelkers; Hugo A Katus; Thomas G Parker; Patrick Most
Journal:  J Cardiovasc Transl Res       Date:  2010-07-20       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.